Black Rock Inc. In8 Bio, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in In8 Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 57,080 shares of INAB stock, worth $131,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,080

Previous 28,204 102.38%

Holding current value

$131,854

Previous $33,000 45.45%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.85 - $1.68 $24,544 - $48,511	28,876 Added 102.38%	57,080 $48,000
Q1 2024 May 10, 2024	SELL	$0.95 - $1.69 $589 - $1,047	-620 Reduced 2.15%	28,204 $33,000
Q4 2023 Feb 13, 2024	SELL	$0.69 - $2.34 $612 - $2,077	-888 Reduced 2.99%	28,824 $39,000
Q3 2023 Nov 13, 2023	SELL	$0.92 - $1.74 $14,148 - $26,759	-15,379 Reduced 34.11%	29,712 $30,000
Q2 2023 Aug 11, 2023	BUY	$1.05 - $3.24 $13,116 - $40,474	12,492 Added 38.32%	45,091 $69,000
Q1 2023 May 12, 2023	BUY	$1.17 - $2.83 $1,249 - $3,022	1,068 Added 3.39%	32,599 $42,000
Q4 2022 Feb 13, 2023	BUY	$1.39 - $2.47 $11,366 - $20,197	8,177 Added 35.01%	31,531 $72,000
Q3 2022 Nov 14, 2022	SELL	$1.77 - $2.89 $9,011 - $14,712	-5,091 Reduced 17.9%	23,354 $47,000
Q2 2022 Aug 12, 2022	BUY	$2.02 - $4.68 $24,464 - $56,679	12,111 Added 74.15%	28,445 $65,000
Q1 2022 May 12, 2022	BUY	$2.76 - $4.6 $18,693 - $31,155	6,773 Added 70.84%	16,334 $54,000
Q4 2021 Feb 10, 2022	BUY	$4.39 - $8.55 $1,097 - $2,137	250 Added 2.68%	9,561 $42,000
Q3 2021 Nov 09, 2021	BUY	$6.71 - $10.0 $62,476 - $93,110	9,311 New	9,311 $64,000

Others Institutions Holding INAB

# of Institutions

Shares Held

2.74M

Call Options Held

Put Options Held

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $56.6M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account